Baseline characteristics of the study population
| Baseline characteristics | UC VDZ (n=41) | UC IFX (n=23) | Controls (n=12) |
|---|---|---|---|
| Male/female (%) | 21/20 (51.2/48.8) | 13/10 (56.5/43.5) | 6/6 (50/50) |
| Median (IQR) age (years) | 40.5 (32–49.4) | 41.3 (31.1–49.6) | 68.2 (59–72.7) |
| Median (IQR) duration of disease (years) | 10.2 (4.4–14.6) | 7.6 (2.8–17.2) | NA |
| Extent of disease | |||
| UC left-sided colitis/pancolitis (%) | 18/23 (43.9/56.1) | 6/17 (26.1/73.9) | NA |
| Histology (Geboes score) | |||
| 0–1 (%) | 0 (0) | 0 (0) | NA |
| 2–5 (%) | 41 (100) | 23 (100) | NA |
| Mayo endoscopic subscore | |||
| 0–1 (%) | 0 (0) | 0 (0) | NA |
| 2–3 (%) | 41 (100) | 23 (100) | NA |
| Median (IQR) total Mayo score | 10 (8–11) | 10 (9–10) | NA |
| Medication (%) | |||
| 5-Aminosalicylates | 29 (70.7) | 18 (78.3) | NA |
| Corticosteroids | 17 (41.5) | 7 (30.4) | NA |
| Azathioprine/6-mercaptopurine | 7 (17.1) | 14 (60.8) | NA |
| Methotrexate | 1 (2) | 0 (0) | NA |
| Anti-TNF | 0 (0) | 0 (0) | NA |
| Active smoking (%) | 5 (12.2) | 2 (8.3) | 0 (0) |
IFX, infliximab; NA, not applicable; TNF, tumour necrosis factor; VDZ, vedolizumab.